Pharmacokinetics and pharmacodynamics of r-HuEPO

A. P. Maxwell, T. R J Lappin*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Recombinant human erythropoietin (r-HuEPO) is now widely used in patients with anaemia resulting from chronic renal failure (CRF), and its value is being tested in a variety of other anaemic conditions. Both the intravenous (IV) and subcutaneous (SC) routes of administration of r-HuEPO are effective despite widely differing bioavailability and pharmacokinetic profiles. Following IV injection, r-HuEPO occupies an apparent volume of distribution equivalent to the plasma volume and has an estimated elimination half-life of 2-13 hours, which tends to increase dose-dependently. SC administration of r-HuEPO is characterised by a prolonged absorption phase, and peak plasma concentrations are typically reached between 12 and 18 hours after injection. In chronic anaemic conditions unrelated to CRF, the pharmacodynamic response to r-HuEPO appears to depend on the baseline serum erythropoietin level, bone marrow responsiveness and iron availability. Algorithms which may help to predict the therapeutic efficacy of r-HuEPO in the individual patient are currently being developed.

Original languageEnglish
Pages (from-to)46-53
Number of pages8
JournalErythropoiesis: New Dimensions in the Treatment of Anaemia
Issue number2
Publication statusPublished - 01 Jan 1995

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Pharmacokinetics and pharmacodynamics of r-HuEPO'. Together they form a unique fingerprint.

Cite this